Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17407557 | 0.98 | PLA2G2A (0.56) | PLA2G2ASMPD1GAATP53TSHR | |
| SCHEMBL19829354 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL1822124 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL9402623 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL7089932 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL15956200 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL2710788 | 0.94 | PLA2G2A (0.66) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL17413301 | 0.92 | PLA2G2A (0.63) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL25327393 | 0.91 | PLA2G2A (0.71) | PLA2G2ASMPD1TP53TSHRPLA2G4B | |
| SCHEMBL317989 | 0.91 | PLA2G2A (0.71) | PLA2G2ASMPD1TP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313652-A1 | Poly-Cyanostilbene Macrocycles | NATIONAL SCIENCE FOUNDATION | 2017-11-02 | — | — | US | disclosed |
| US-9701621-B2 | Poly-cyanostilbene macrocycles | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150376122-A1 | Poly-Cyanostilbene Macrocycles | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376122-A1 | Poly-Cyanostilbene Macrocycles | PCBP1, HCCS, ACVR2B | PLA2G2A 4857/4885SMPD1 4869/4885GAA 2780/4885 |
| US-20170313652-A1 | Poly-Cyanostilbene Macrocycles | PCBP1, HCCS, ACVR2B | PLA2G2A 4857/4885SMPD1 4869/4885GAA 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.